Skip to main content
M

MedicSen

MedicSen has developed a needle-free, wearable drug delivery device that utilizes harmless ultrasound waves to temporarily enlarge skin pores, allowing macromolecules like insulin and heparin to be absorbed transdermally. This technology addresses the challenge of painful injections for patients, particularly those with diabetes, by providing a painless and safe alternative for medication administration.

Madrid, SpainFounded 2014203K+ followers
Updated 3 months ago

Funding

$5.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Many medications, such as insulin and heparin, require frequent injections, which can be painful and inconvenient for patients, especially those with chronic conditions like diabetes. Traditional needle-based drug delivery can lead to poor patient compliance and reduced quality of life.

Solution

MedicSen has developed a wearable, needle-free drug delivery device that uses harmless ultrasound waves to temporarily enlarge skin pores, enabling transdermal absorption of macromolecules up to 200 kDa. The device is designed to be comfortable and discreet, measuring approximately 4x2x1 cm. By creating transient pores in the skin, the device allows medications like insulin and heparin to be absorbed without the need for injections. The pores close naturally when the device stops emitting ultrasound waves, ensuring a safe and painless drug delivery method.

Target Audience

The primary target audience includes individuals with diabetes requiring frequent insulin injections, as well as patients needing other macromolecule medications like heparin, who seek a painless and convenient alternative to traditional needle-based injections.

Features

  • Wearable patch design for convenient and discreet drug administration
  • Needle-free delivery via harmless ultrasound waves
  • Temporary enlargement of skin pores to facilitate macromolecule absorption
  • Transdermal delivery of drugs up to 200 kDa, including insulin and heparin
  • Painless and safe drug delivery method
  • Pores close naturally after device use
This profile is AI-generated and may contain inaccuracies.